Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

AbbVie Profit Meets Analysts’ Estimates on Humira Sales

Don't Miss Out —
Follow us on:

Jan. 31 (Bloomberg) -- AbbVie Inc. reported fourth-quarter profit that met analysts’ estimates on increased revenue from the company’s top drug, Humira for rheumatoid arthritis.

Earnings excluding one-time items were 82 cents a share, matching the average of nine estimates compiled by Bloomberg. The company, which split from parent Abbott Laboratories last year, forecast 2014 profit of $3 to $3.10 a share, North Chicago, Illinois-based AbbVie said today in a statement. Analysts had estimated $3.13.

Fourth-quarter revenue of $5.11 billion was boosted by a 13 percent increase in Humira sales. Humira helps protect AbbVie from the patent losses that have hurt companies such as Eli Lilly & Co. and Pfizer Inc. because the biotechnology medicine won’t face the same competition from inexpensive copycats as traditional drugs. AbbVie also said it may have its hepatitis C combination therapy on the market this year.

“Two story lines dominate –- the strength of Humira revenues in the here and now, and pipeline developments to fill potential shortfalls going forward,” said Tony Butler, an analyst with Barclays Plc who has an equal-weight rating on the stock. This year there will be major results for experimental medicines in hepatitis C and cancer, Butler said in a note to clients.

AbbVie shares gained 1.9 percent to $49.23 at the close in New York.

Gilead Race

The company is racing against Gilead Sciences Inc. to be the first to market with a multi-drug hepatitis C treatment that doesn’t need the use of older medicines and has at least a 90 percent chance of clearing the virus.

AbbVie said it plans to submit the drug for U.S. Food and Drug Administration approval in the second quarter. while Foster City, California-based Gilead has said it can file in the first quarter.

AbbVie completed the final-stage studies of the three-drug treatment, testing the regimen with and without ribavirin, an older medicine used to boost the virus-clearing effect. In six trials of different treatments and patient types, the regimen cleared all signs of the virus in 90 percent to 100 percent of patients, the company said.

AbbVie generates almost 60 percent of its revenue from Humira, which had $9.27 billion in sales in 2012.

That has buoyed the company’s stock since it become an independent company at the start of 2013. AbbVie shares gained 34 percent in the last 12 months.

Net income declined 27 percent to $1.13 billion, or 70 cents a share, from $1.54 billion, or 98 cents, a year earlier, the company said.

To contact the reporter on this story: Drew Armstrong in New York at darmstrong17@bloomberg.net

To contact the editor responsible for this story: Reg Gale at rgale5@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.